World Bipolar day is celebrated on March 30, the birthday of Dutch artist Vincent Van Gogh who died by suicide at 37 and was posthumously diagnosed as probably having a bipolar disorder. Bipolar disorder is a brain disorder that causes changes in a person’s mood, energy and ability to function.
NRx Pharmaceuticals, Inc. today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 11,576,911. This patent, issued to Glytech LLC, is exclusively licensed to NeuroRx, Inc., a wholly owned subsidiary of NRx, under the terms of a license agreement with Glytech through which NeuroRx has the sole rights to this and other patents, both U.S. and international.
NRx Pharmaceuticals, Inc. today reported the recommendations of an independent Data Safety Monitoring Board (DSMB) which reviewed the safety findings of the first fifty enrolled participants in the Company’s phase 2 clinical trial of NRX-101.
NRx Pharmaceuticals, Inc. today announced that it had a meeting and a written response from the Food and Drug Administration (FDA) last week regarding its lead compound, NRX-101.
NRx Pharmaceuticals, Inc. today announced it has initiated a Phase 3 registrational trial targeting suicidal bipolar depression with suicidality and has signed the first clinical site contract.
See our Chief Scientist, Dr. Jonathan C. Javitt, provide a comprehensive description on why we are committed to solve for a very high unmet need in bipolar depression with suicidality.
NRx Pharmaceuticals enrolled its first patient in one of two psychiatry studies being initiated this year; this first trial is studying patients with bipolar depression and sub-acute suicidality.
RADNOR, Pa., Nov. 16, 2021 (GLOBE NEWSWIRE) — NRx Pharmaceuticals (Nasdaq: NRXP) (NRx), a clinical-stage, biopharmaceutical company, today provided a business update and financial results for the quarter ended September 30, 2021. NRx will host a conference call Tuesday morning, November 16th, at 8:30 AM Eastern Time to discuss its business update and third-quarter financial […]
RADNOR, Pa., Aug. 24, 2021 /PRNewswire/ — NRx Pharmaceuticals (Nasdaq: NRXP), today announced that it has completed its previously announced private placement for the purchase of 2,727,273 shares of common stock. The Company issued to the investors in the private placement unregistered preferred investment options (the “investment options”) to purchase up to an aggregate of 2,727,273 shares of […]
